Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alina Iovleva

Showing results (11-20 of 26) with videos related to

Pageof 3
Sort By:
Medical Mycology Case Reports|April 30, 2019
<i>Rasamsonia</i> sp: An emerging infection amongst chronic granulomatous disease patients. A case of disseminated infection by a putatively novel <i>Rasamsonia argillacea</i> species complex involving the heartAhmed Babiker, Nupur Gupta, Connie F C Gibas, et al.
PHAGE (New Rochelle, N.Y.)|September 23, 2022
Isolation and Characterization of Lytic Bacteriophages Targeting Diverse <i>Enterobacter</i> spp. Clinical IsolatesAmanda G Finney, Jalyne M Perry, Daniel R Evans, et al.
The Journal of Antimicrobial Chemotherapy|May 26, 2019
Reduced ceftazidime and ertapenem susceptibility due to production of OXA-2 in Klebsiella pneumoniae ST258Alina Iovleva, Roberta T Mettus, Christi L McElheny, et al.
Antimicrobial Agents and Chemotherapy|October 23, 2019
High-Level Carbapenem Resistance in OXA-232-Producing Raoultella ornithinolytica Triggered by Ertapenem TherapyAlina Iovleva, Roberta T Mettus, Christi L McElheny, et al.
Antimicrobial Agents and Chemotherapy|May 11, 2021
Characterization of KPC-82, a KPC-2 Variant Conferring Resistance to Ceftazidime-Avibactam in a Carbapenem-Nonsusceptible Clinical Isolate of Citrobacter koseriFrancois Lebreton, Brendan W Corey, Christi L McElheny, et al.
Microbial Genomics|September 28, 2022
IS<i>26</i>-mediated plasmid reshuffling results in convergence of toxin-antitoxin systems but loss of resistance genes in XDR <i>Klebsiella pneumoniae</i> from a chronic infectionTing L Luo, Brendan W Corey, Erik Snesrud, et al.
The Journal of Antimicrobial Chemotherapy|March 4, 2023
Early initiation of three-drug combinations for the treatment of carbapenem-resistant A. baumannii among COVID-19 patientsEmily L Heil, Kimberly C Claeys, Ellen G Kline, et al.
Infection and Immunity|December 11, 2024
Prevalence and features of hypervirulent <i>Klebsiella pneumoniae</i> in respiratory specimens at a US hospital systemChristi L McElheny, Alina Iovleva, Nathalie Chen, et al.
Jac-Antimicrobial Resistance|September 10, 2024
Frequency of cefiderocol heteroresistance among patients treated with cefiderocol for carbapenem-resistant <i>Acinetobacter baumannii</i> infectionsRyan K Shields, Ava J Dorazio, Giusy Tiseo, et al.
Iscience|May 27, 2022
Genomic characterization of lytic bacteriophages targeting genetically diverse <i>Pseudomonas aeruginosa</i> clinical isolatesHayley R Nordstrom, Daniel R Evans, Amanda G Finney, et al.
Pageof 3

Showing results (11-20 of 26) with videos related to

Sort By:
Pageof 3
Medical Mycology Case Reports|April 30, 2019
<i>Rasamsonia</i> sp: An emerging infection amongst chronic granulomatous disease patients. A case of disseminated infection by a putatively novel <i>Rasamsonia argillacea</i> species complex involving the heartAhmed Babiker, Nupur Gupta, Connie F C Gibas, et al.
PHAGE (New Rochelle, N.Y.)|September 23, 2022
Isolation and Characterization of Lytic Bacteriophages Targeting Diverse <i>Enterobacter</i> spp. Clinical IsolatesAmanda G Finney, Jalyne M Perry, Daniel R Evans, et al.
The Journal of Antimicrobial Chemotherapy|May 26, 2019
Reduced ceftazidime and ertapenem susceptibility due to production of OXA-2 in Klebsiella pneumoniae ST258Alina Iovleva, Roberta T Mettus, Christi L McElheny, et al.
Antimicrobial Agents and Chemotherapy|October 23, 2019
High-Level Carbapenem Resistance in OXA-232-Producing Raoultella ornithinolytica Triggered by Ertapenem TherapyAlina Iovleva, Roberta T Mettus, Christi L McElheny, et al.
Antimicrobial Agents and Chemotherapy|May 11, 2021
Characterization of KPC-82, a KPC-2 Variant Conferring Resistance to Ceftazidime-Avibactam in a Carbapenem-Nonsusceptible Clinical Isolate of Citrobacter koseriFrancois Lebreton, Brendan W Corey, Christi L McElheny, et al.
Microbial Genomics|September 28, 2022
IS<i>26</i>-mediated plasmid reshuffling results in convergence of toxin-antitoxin systems but loss of resistance genes in XDR <i>Klebsiella pneumoniae</i> from a chronic infectionTing L Luo, Brendan W Corey, Erik Snesrud, et al.
The Journal of Antimicrobial Chemotherapy|March 4, 2023
Early initiation of three-drug combinations for the treatment of carbapenem-resistant A. baumannii among COVID-19 patientsEmily L Heil, Kimberly C Claeys, Ellen G Kline, et al.
Infection and Immunity|December 11, 2024
Prevalence and features of hypervirulent <i>Klebsiella pneumoniae</i> in respiratory specimens at a US hospital systemChristi L McElheny, Alina Iovleva, Nathalie Chen, et al.
Jac-Antimicrobial Resistance|September 10, 2024
Frequency of cefiderocol heteroresistance among patients treated with cefiderocol for carbapenem-resistant <i>Acinetobacter baumannii</i> infectionsRyan K Shields, Ava J Dorazio, Giusy Tiseo, et al.
Iscience|May 27, 2022
Genomic characterization of lytic bacteriophages targeting genetically diverse <i>Pseudomonas aeruginosa</i> clinical isolatesHayley R Nordstrom, Daniel R Evans, Amanda G Finney, et al.
Pageof 3